IMMUNITYBIO, INC. Available-for-sale Securities and Held-to-maturity Securities
IMMUNITYBIO, INC. (IBRX) had Available-for-sale Securities and Held-to-maturity Securities of $80.46 million as of 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAndHeldToMaturitySecurities · last filed 2019-05-08
- 2019-03-31: Available-for-sale Securities and Held-to-maturity Securities $80.46M.
- 2018-12-31: Available-for-sale Securities and Held-to-maturity Securities $63.75M.
- 2018-09-30: Available-for-sale Securities and Held-to-maturity Securities $81.31M.
| Period end | Available-for-sale Securities and Held-to-maturity Securities |
|---|---|
| 2019-03-31 | $80.46M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $63.75M 10-Q · filed 2019-05-08 |
| 2018-09-30 | $81.31M 10-Q · filed 2018-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |